Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Agios Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Agios Pharmaceuticals, Inc.’s stock price such as:

• Agios Pharmaceuticals, Inc.’s current stock price and volume
• Why Agios Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for AGIO from analysts
• AGIO’s stock price momentum as measured by its relative strength

About Agios Pharmaceuticals, Inc. (AGIO)

Before we jump into Agios Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Want to learn more about Agios Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Agios Pharmaceuticals, Inc..

Agios Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of May 08, 2026, 2:43 PM, CST, Agios Pharmaceuticals, Inc.’s stock price was $27.630.

Agios Pharmaceuticals, Inc. is up 0.36% from its previous closing price of $27.530.

During the last market session, Agios Pharmaceuticals, Inc.’s stock traded between $27.500 and $28.210. Currently, there are approximately 58.78 million shares outstanding for Agios Pharmaceuticals, Inc..

Agios Pharmaceuticals, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Agios Pharmaceuticals, Inc. Stock Price History

Agios Pharmaceuticals, Inc.’s (AGIO) price is currently down 1.32% so far this month.

During the month of May, Agios Pharmaceuticals, Inc.’s stock price has reached a high of $28.400 and a low of $26.510.

Over the last year, Agios Pharmaceuticals, Inc. has hit prices as high as $46.000 and as low as $22.240. Year to date, Agios Pharmaceuticals, Inc.’s stock is up 1.51%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Agios Pharmaceuticals, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 07, 2026, there was 1 analyst who downgraded Agios Pharmaceuticals, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Agios Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Agios Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Agios Pharmaceuticals, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Agios Pharmaceuticals, Inc. (AGIO) by visiting AAII Stock Evaluator.

Relative Price Strength of Agios Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 07, 2026, Agios Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of -4.26%, which translates to a Momentum Score of 43 and is considered to be Average.

Want to learn more about how Agios Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Agios Pharmaceuticals, Inc. Stock Price: Bottom Line

As of May 8, 2026, Agios Pharmaceuticals, Inc.’s stock price is $27.630, which is up 0.36% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Agios Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.